S38 A phase IIa study of AVONEX (interferon-B-1a) in ulcerative colitis (UC): Integrating basic immunology and human pilot study results
Fabio Cataldi(Pfizer (United States)), Warren Strober(Office of Extramural Research), Catherine Groden, Peter Mannon(University of Nebraska–Lincoln), Ivan J. Fuss(National Institutes of Health)
Cited by 1
Related Papers
Cell Contact–Dependent Immunosuppression by Cd4+Cd25+Regulatory T Cells Is Mediated by Cell Surface–Bound Transforming Growth Factor β
|The Journal of Experimental Medicine|2001|1.6k
Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples
|Genome biology|2012|1.1k
Anti–Interleukin-12 Antibody for Active Crohn's Disease
|New England Journal of Medicine|2004|853
Experimental Models of Inflammatory Bowel Diseases
|Cellular and Molecular Gastroenterology and Hepatology|2015|704